Formulary Search - PAD Formulary

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Clostridioides difficile (Fidaxomicin - Clostridioides difficile)

Records returned : 3 (on 21 Nov 2024 at 21:15:30). Return to search results for ' Clostridioides difficile '.

Drug

Indication

Status

Trust Alignment

Links

Restrictions/Comments

05.01.07

Fidaxomicin

Clostridioides difficile

Green

Formulations :

Oral suspension
Tablets

ASPH

RSFT

SASH

SABP

Primary Care

BNF SPC

Important

Granules (for oral suspension) should be used in patients requiring a liquid preparation. Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. For any patient requiring a liquid preparation, fidaxomicin granules should be prescribed. The APC notes that although current NICE guidelines recommend vancomycin first line, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.

05.01.07

11.03.01

Vancomycin hydrochloride

Clostridioides difficile

Green

Formulations :

Capsules

ASPH

RSFT

SASH

SABP

Primary Care

BNF SPC

Important

Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. The APC notes that although current NICE guidelines recommend vancomycin first line for treatment of C diff, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.

Bezlotuxumab

Clostridioides difficile

Non Formulary

Formulations :

Not Specified

ASPH

RSFT

SASH

SABP

Primary Care

BNF SPC

NFD1

Important

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed with NICE recommendation not to use bezlotoxumab to prevent recurrence of C. Difficile infection because it is not cost effective. Bezlotoxumab will be given a NON-FORMULARY traffic light status for this indication.

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off-label use. Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

ICB

Treatment commissioned by the ICB

BlueTeq

BlueTeq form to be completed

NICE

Traffic Light Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Black

Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.

Amber Star

Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)

See Below

Please add a description.

N/A

Please add a description.

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

Green - Black

Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.

See narrative

See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)

Do not initiate in new patients

These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)